Portopulmonary Hypertension

Cardiovascular
4
Pipeline Programs
2
Companies
3
Clinical Trials
1
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
2
2
Early DiscoveryClinical DevelopmentMarket

On Market (1)

Approved therapies currently available

GS
LETAIRISApproved
ambrisentan
Gilead Sciences
Endothelin Receptor Antagonist [EPC]oral2007

Competitive Landscape

2 companies ranked by most advanced pipeline stage

GS
Gilead SciencesFOSTER CITY, CA
3 programs
2
1
Ambrisentan PillPhase 41 trial
AmbrisentanPhase 31 trial
AmbrisentanPhase 3
Active Trials
NCT01224210Completed30Est. Mar 2020
NCT03309592Withdrawn0Est. Nov 2018
United Therapeutics
United TherapeuticsMD - Silver Spring
1 program
TreprostinilN/A1 trial
Active Trials
NCT01028651Completed13Est. Apr 2013

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Gilead SciencesAmbrisentan Pill
Gilead SciencesAmbrisentan
United TherapeuticsTreprostinil

Clinical Trials (3)

Total enrollment: 43 patients across 3 trials

NCT03309592Gilead SciencesAmbrisentan Pill

Efficacy and Safety of Combination Ambrisentan and Tadalafil in Patients With Portopulmonary Hypertension

Start: Oct 2017Est. completion: Nov 20180
Phase 4Withdrawn
NCT01224210Gilead SciencesAmbrisentan

Ambrisentan in Patients With Porto-pulmonary Hypertension A Multicenter Open Label Trial

Start: Mar 2010Est. completion: Mar 202030 patients
Phase 3Completed
NCT01028651United TherapeuticsTreprostinil

A Study to Assess the Safety and Efficacy of Treprostinil to Facilitate Liver Transplantation in Patients With Portopulmonary Hypertension

Start: Jan 2011Est. completion: Apr 201313 patients
N/ACompleted

Related Jobs in Cardiovascular

Embedded Software and System Test Engineer (H/F)

Cardiawave
Levallois-Perret, France (Hybrid)
Just now

Territory Sales Manager - Iowa / Nebraska

HeartFlow
Cedar Rapids, IA; Des Moines, IA; Omaha, NE; Lincoln, NE
Yesterday
From $150K/yr

Associate Regulatory Affairs Specialist

Medtronic
Mounds View, Minnesota, United States of America
Yesterday
$60K - $90K/yr

Business Development Manager, Post Transplant, Cardio Thoracic

Thermo Fisher Scientific
Remote
Yesterday

Director, Medical Affairs

Abbott
Germany - Hesse - Eschborn
Yesterday

Therapy Development Manager

Abbott
Australia > Doncaster : 666 Doncaster Road
Yesterday

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 late-stage (Phase 3) programs — potential near-term approvals
2 companies competing in this space

Related Indications

Hypertension(361)Heart Failure(347)Coronary Artery Disease(302)Atrial Fibrillation(290)Pulmonary Arterial Hypertension(106)Acute Coronary Syndrome(67)Pulmonary Hypertension(57)Atherosclerosis(44)Hypertension, Pulmonary(34)Essential Hypertension(32)